# Novo raises full-year outlook as Wegovy pill sales impress

- URL: https://talkfuse.com/story/novo-raises-full-year-outlook-as-wegovy-pill-sales-impress/
- Published: 2026-11-04T07:14:57+00:00
- Updated: 2026-11-06T04:05:14+00:00
- Original publisher: CNBC (publisher lean: Centre)
- Original article: https://www.cnbc.com/2026/11/04/novo-q3-earnings-wegovy-sales.html
- Topics: Business, Companies

## Key points

- Wegovy pill sales beat estimates.
- Novo raised its full-year outlook.
- CagriSema faces questions about its competitiveness.

## Summary

Novo Nordisk reported third-quarter earnings above expectations, helped by strong sales of its Wegovy pill, and raised its full-year outlook. The results suggest the Danish drugmaker is gaining sales momentum as it tries to compete with Eli Lilly in the growing weight-loss treatment market.

Revenue reached 79.2 billion Danish kroner, up 4% year on year at constant exchange rates, while adjusted operating profit was 31.7 billion kroner. Novo now expects adjusted revenue and operating profit growth of between -2% and 2%, compared with its previous forecast of -6% to flat. Shares rose by as much as 6% in early trading; the company said it held 80% US market share, and investors are watching its planned CagriSema launch amid questions about how it will fare against Lilly’s drugs.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.